'Important' Alzheimer's Treatment Breakthrough Gets FDA Approval
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The U.S. Food and Drug Administration (FDA) approved the first blood test to detect Alzheimer's disease in what federal officials called an "important step" toward diagnosing and treating the disease earlier.
Developed by Fujirebio Diagnostics, the test analyzes the ratio of two proteins in a patient's blood, a measurement that correlates with the presence of amyloid plaques in the brain.
These plaques are a hallmark of Alzheimer's and previously required either costly positron emission tomography (PET) scans, or invasive spinal fluid analysis for confirmation.
The newly approved test can be used in clinics for patients showing signs of cognitive decline. The results are intended to be interpreted alongside other clinical assessments.
Stock image: Jigsaw puzzle representing brain and mental health.
Stock image: Jigsaw puzzle representing brain and mental health.
Photo by designer491 / Getty Images
Why It Matters
The approval could accelerate the diagnosis process for a disease that impacts more than 6 million Americans and is expected to affect twice as many by 2050.
Early diagnosis is crucial for patients to begin treatment with existing therapies that, while not curative, have been shown to slow cognitive decline.
"Alzheimer's disease impacts too many people—more than breast cancer and prostate cancer combined," said FDA Commissioner Marty Makary, in the agency's press release.
Diana Dickson, vice president of clinical and regulatory sciences at Fujirebio Diagnostics, noted the "millions" of people impacted by Alzheimer's, in addition to patients.
"Millions of patients, family members and caregivers are impacted by this terrible disease and, unfortunately, low-invasive, accessible and affordable diagnostic tools have not been readily available," Dickson told Newsweek in an email.
"With this FDA clearance, this test becomes available to physicians through any CLIA [Clinical Laboratory Improvement Amendments] laboratory, which enables access to plasma testing."
What To Know
The test is meant for use in people already showing signs of cognitive impairment. It should be used as part of a broader diagnostic work-up that includes clinical evaluation and possibly additional imaging.
The approval comes as two Alzheimer's drugs—lecanemab and donanemab—are already authorized by the FDA. Both are antibody therapies that target amyloid plaques and are believed to be more effective when administered earlier in the disease's progression.
Clinical studies found that the blood test's accuracy was comparable to PET imaging and spinal fluid testing.
What People Are Saying
Michelle Tarver, of the FDA's Center for Devices and Radiological Health, said: "Today's clearance is an important step for Alzheimer's diagnosis, making it easier and potentially more accessible for U.S. patients earlier in the disease."
Makary said: "Knowing that 10% of people aged 65 and older have Alzheimer's and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients."
Dickson said the test is the culmination of more than 30 years of commitment by Fujirebio in the fight against Alzheimer's.
"The battle is not nearly over," she continued, "There is much work to be done, not only with this test, but in the development of other novel biomarkers for use in other pathologies and in other neurodegenerative disease.
"We continue to be committed to these efforts and are immensely grateful for the partnerships with the pharmaceutical, research and patient communities that have made and continue to make these advances possible."
What Happens Next
The blood test is now authorized for use in clinical practice, but adoption will depend on further integration into care pathways, insurance coverage decisions and physician familiarity.
Dickson said Fujirebio is working to create packaging and inserts to send out their first shipments. The Pennsylvania-headquartered company is finding partners to make sure the clinical data drawn from the tests can be published and discussed within the clinical community.
"Finally, we are engaged with various patient advocacy groups and medical specialties to ensure that the public is aware of the test, how it should and should not be used and how results are best interpreted," Dickson said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
32 minutes ago
- CNN
FDA official returns to agency after Loomer-led ouster
Federal agencies ActivismFacebookTweetLink Follow Dr. Vinay Prasad, a controversial critic of the US Food and Drug Administration who took a top role at the regulatory agency in May, has returned to his job weeks after resigning amid pressure from the White House and right-wing activist Laura Loomer. 'At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,' said Health and Human Services spokesperson Andrew Nixon in a statement to CNN on Saturday. Nixon did not respond to CNN's inquiry about whether Prasad will also return to his role as FDA chief medical and scientific officer. In late July, Prasad, a hematologist oncologist, said he was resigning because he 'did not want to be a distraction to the great work of the FDA' and had 'decided to return to California and spend more time with his family.' Prasad's departure came amid fresh pressure from the White House for him to resign, according to a person familiar with the matter who was granted anonymity to describe the internal dynamics, and followed days of criticism from Loomer, who has extraordinary access to President Donald Trump. Loomer had taken shots at Prasad on her website and on social media, attacking him publicly for days as a 'progressive leftist saboteur' who was 'undermining President Trump's FDA.' Loomer focused on Prasad's previous social media posts and podcast episodes, where she said he aligned himself politically with liberal politicians and expressed 'disdain' for Trump. Her posts were followed by others from figures including former US Sen. Rick Santorum, who called Prasad 'the man destroying @POTUS legacy for helping patients,' and a Wall Street Journal opinion piece headlined, 'Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag.' Prasad had been a vocal critic of some of the agency's drug approvals, as well as the government's response and vaccine policies during the Covid-19 pandemic. Loomer, reacting to the news of Prasad's return in a Saturday post on X, called it an 'egregious personnel decision' and said she planned to '(ramp) up my exposes of officials within HHS and FDA' in the coming weeks. Prasad also drew criticism from former officials and vaccine experts after internal memos from May revealed that he overrode FDA scientists on recommendations for two new versions of Covid-19 vaccines. The then-CBER director rebuked recommendations for broad use of the shots; the FDA eventually approved the vaccines for use in older and immunocompromised people but did not advise them for younger Americans who don't have underlying conditions. CNN's Meg Tirrell, Sarah Owermohle, and Adam Cancryn contributed to this report.
New York Post
33 minutes ago
- New York Post
Trying to lose weight? This common mealtime mistake could be sabotaging your progress
Lifestyle choices impact your weight, but your genes can tip the scales, too. New research suggests that people with a higher risk for obesity may be sabotaging their efforts to slim down by making a simple mealtime mistake. The good news? Scientists found an easy switch that can help fight back against what's written in your DNA — and it's not about changing what's on your plate. Advertisement 3 While lifestyle factors like diet and exercise are crucial, genetics can influence a person's predisposition to weight gain Creativa Images – The study followed nearly 1,200 overweight and obese adults in Spain taking part in a 16-week weight-loss program. About 80% were women, with an average age of 41. Researchers calculated each person's polygenic risk score for body mass index (BMI) — a genetic measure of their obesity risk. Advertisement They also tracked when participants ate, splitting them into 'early' and 'late' eaters based on the midpoint between their first and last meals of the day. After a 12-year follow-up, participants gained 2.2% more body weight for every hour that their meal midpoint was delayed. 3 Eating earlier in the day is linked to better long-term weight loss success, researchers found. ayselucar – The researchers also found a 'significant interaction' between meal timing and genetic risk scores. Advertisement Over the study period, participants with a high genetic predisposition for obesity saw their BMI increase by more than 2 points for every hour they delayed eating. No such link was observed in those with lower genetic risk. People with both a high genetic risk and later meal times had the highest BMI, while early eaters kept theirs lower. 'These findings suggest that early eating may be especially relevant for individuals with a genetic predisposition for obesity and not for others,' the study authors wrote. 3 Projections indicate that the majority of US adults will be overweight or obese by 2050. chathuporn – Advertisement The implications are serious. Across the country, more than 100 million adults have obesity, and over 22 million have severe obesity, according to the Centers for Disease Control and Prevention. This extra weight increases their risk for a wide range of chronic health conditions, including type 2 diabetes, heart disease, stroke, high blood pressure and even some cancers. It also drives up healthcare costs. In 2019, adults with obesity spent an average of $1,861 more per year on medical care than those at a healthy weight. For those with severe obesity, excess costs topped $3,000 per person. Without strong interventions, the problem is only expected to grow worse. While surveys have found that many overweight Americans want to slim down, research shows that conventional methods like calorie restriction often fail to keep the weight off long-term. The study authors said that understanding the link between genetic risk for obesity and meal timing could pave the way for personalized prevention and targeted behavioral interventions in the future. One example they highlighted is precision nutrition, which designs eating plans based on a person's DNA, microbiome, and metabolic responses — moving beyond the one-size-fits-all approach.
The Hill
33 minutes ago
- The Hill
FDA reinstates ousted top vaccine regulator Vinay Prasad
Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to his post, according to the Department of Health and Human Services (HHS). 'At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,' an HHS spokesperson told The Hill in a statement. 'Neither the White House nor HHS will allow the fake news media to distract from the critical work the FDA is carrying out under the Trump administration.' Prasad's July 30 resignation as the FDA's chief science officer followed criticism from right-wing figures — including activist Laura Loomer and former Sen. Rick Santorum (R-Pa.) — that ran parallel to a regulatory showdown with drug manufacturers over a gene therapy treatment for boys with Duchenne muscular dystrophy. Loomer, a key ally of President Trump with noticeable influence, lavished attacks on the FDA official in recent weeks — calling him a 'saboteur' and 'trojan horse' for HHS's 'Make America Healthy Again' initiative. Prasad was named head of the FDA's Center for Biologics Evaluation and Research in early May as a replacement for Peter Marks, who resigned from the position in March after clashing with HHS Secretary Robert F. Kennedy Jr. The doctor, just one of several health officials tapped by Trump who criticized COVID-19 vaccines, had been in the role for less than three months when the FDA announced he would step down. 'Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,' an HHS spokesperson said at the time. 'We thank him for his service and the many important reforms he was able to achieve in his time at FDA.' The division at the time was also involved in a dispute between the administration and Sarepta Therapeutics. The FDA had paused shipments and clinical trials of its Elevidys treatment for those with Duchenne muscular dystrophy following reports of two patients that died after receiving the drug. Prior to his role in the administration, Prasad had argued against the treatment's approval after Marks overrode multiply agency reviews. He also recently made headlines for restricting the approval of two COVID-19 vaccines while disregarding recommendations from government scientists. Two memos issued last month by the FDA showed how the doctor personally intervened to place limitations on drugmakers Novavax and Moderna after their coronavirus shots were approved for anyone 12 years or older.
